Archive for January, 2021

$HWAL Is ‘One to Watch’

January 29, 2021

Hollywall Entertainment Inc. (HWAL) Is ‘One to Watch’

  • Hollywall Entertainment Inc. is currently working on expanding the company through the acquisition of businesses within its targeted industries
  • Hollywall subsidiaries are already working on multiple projects, most notably its HWDC subsidiary’s focus on the smart city concept leveraging 5G technology, internet of things and other innovative technologies
  • The global 5G market is estimated to reach $414.5 billion by 2027, achieving a CAGR of 43.9%
  • The company has acquired Omnipoint Technology and has launched HW Vision, a unique provider of state-of-the-art telecommunications services
  • The music catalog licenses held by Hollywall Music and the Hollywall Network include rare recordings and unreleased tracks that are in high demand

Hollywall Entertainment (OTC: HWAL) is a telecommunication, media, technology, broadcasting and entertainment company. Through various subsidiaries, Hollywall maximizes rights to its music, film, television, software and game libraries. Hollywall owns exclusive and nonexclusive rights to market, manufacture and distribute music master recordings performed by multiple platinum-selling acts.

Hollywall was founded in 2009. The company currently has two corporate offices – one in Washington D.C. and the other in New York City.

Hollywall Entertainment Inc. (Hollywall) Subsidiaries

Hollywall has a portfolio of operating subsidiaries spanning various industries, including infrastructure development, 5G and telecommunications, broadcasting, education, media and entertainment.

Hollywall is a minority majority-controlled consortium enterprise company led by founder and President/CEO Darnell Sutton, a highly recognized visionary and award-winning business and social leader.

HWAL continues to expand its business enterprise to numerous city and state municipalities and government agencies throughout the country, including: Washington DC, New York, Virginia, Massachusetts, Pennsylvania, Texas and California, as well as within the Blackbelt regions of Alabama, Louisiana, Mississippi, Georgia and North Carolina, leading the way in developing and implementing solutions to work toward closing the broadband digital divide that has been forced upon the most vulnerable in underserved urban and rural communities nationwide.

Hollywall Development Company (“HWDC”)

HWDC builds, restores and creates “smart” cities/communities and fiber networks throughout the U.S. HWDC services, initiatives and investments include broadband and 5G networks, IOT, smart city technologies, energy, tele-medicine, tele-education, transportation, clean water, waste management and the development of green environments.

HWDC employment growth opportunities continue to attract the industry’s best, brightest and most seasoned corporate executives to join its staff, as well as its ongoing efforts to develop highly effective and profitable strategic partnerships with investment banks, global capital funds, public financial and wealth management firms, construction and engineering companies, telecommunications companies, federal agencies, state and local governments, nonprofits, faith-based organizations and housing authorities.

HWDC’s Smart Cities division aims to provide various services and solutions, such as fiber-optic networking, data centers, smart kiosks, charging stations, security and camera systems, smart traffic monitoring, emergency alert systems, gunshot detection, backup power solutions, smart connected buildings, connected and autonomous vehicles, intelligent transportation systems, advertising and more.

HW Vision and Omnipoint Technology Inc.

Hollywall Entertainment advanced its technological footprint by acquiring top United States telecommunications firm Omnipoint Technology Inc. in 2020. Through the formation of a new wholly owned subsidiary, HW Vision, Hollywall intends to offer state-of-the-art services in the continuously growing digital marketplace, such as:

  • 5G and Fiber Network installation services
  • Affordable high-speed internet access
  • Telehealth services
  • Domain hosting
  • Web conferencing
  • Managed internet services
  • Nationwide unlimited talk, text and data cellphone plans
  • Video broadcasting

In conjunction with its Omnipoint Technology partner, HW Vision has created and developed unique branding for streaming media programming, live television and on-demand content. Offerings from the HW Vision brand are expected to be available for purchase early in 2021.

Hollywall Entertainment Digital Music Network and Hollywall TV

The Hollywall Entertainment Digital Music Network (“HW Network”) has been constructed to sell single song downloads, artist album downloads and ringtones, as well as licensing music for commercial use. Hollywall Music is an owner of legacy music and video collector sets that are distributed to retail, wholesale and download or streaming services. This music library has been protected for over 20 years, and it contains some of the rarest and most coveted unpublished records by legends in the music industry.

Market Outlook

Covering various industries that are continuously expanding, such as telecommunications, media, technology, construction, infrastructure, entertainment and broadcasting, Hollywall is uniquely positioned to secure a prominent role and leverage continued growth opportunities for its subsidiaries.

The 5G sector alone could generate significant interest and market opportunities for Hollywall via HWDC and its community-focused initiatives, including the development of smart cities. The global 5G market was estimated at $41.48 billion for 2020 and is expected to reach an impressive $414.5 billion by 2027, expanding at a CAGR of 43.9% (https://ibn.fm/mgXIu).

Management Team

Darnell Sutton is the Founder, CEO and Chairman of Hollywall Entertainment Inc. Mr. Sutton has over 40 years’ experience with many talents and vast experience as a veteran in the music recording industry, publishing, distribution, live entertainment, television, broadcasting, film and sports athlete, TV/film celebrity and artist management.

Darnell Sutton has represented and worked with some of the greatest athletes and entertainers of our time, including the “King of Pop” Michael Jackson, former heavyweight boxing champion Mike Tyson, current Welterweight Boxing Champion Floyd Mayweather, tennis superstar Serena Williams, Julius “Dr. J” Erving and incomparable multiple Grammy award-winning performers such as The Jacksons, Patti Labelle, Roberta Flack, MC Hammer, Dionne Warwick and Mariah Carey… just to name a few.

“Darnell Sutton, is one of the most exciting master communicators, creative developers and innovators of our time”…says, Tom Stein, Success Magazine.

“After many years of developing, producing and acquiring some of the world’s finest entertainment properties, we are honored to present Hollywall Entertainment companies to the marketplace. We are thrilled to join forces and work with some of the most brilliant and talented Hollywood and Wall Street executives, who have a combined shared experience of industry-recognized excellence,” Sutton said in a news release.

Roxanna Green is the Chief of Staff for Hollywall Entertainment Inc. She has over 30 years of diverse background experience ranging from corporate management to finance. Her experience includes providing corporate legal and financial guidance to both public and private companies, as well as spearheading audits, merger and acquisition negotiations, branding, marketing and public relations initiatives. She has spent the majority of her 30 years in the entertainment and media industry. She has worked with diverse institutions such as banks and securities firms, among others.

For more information, visit the company’s website at www.Hollywall.com.

NOTE TO INVESTORS: The latest news and updates relating to HWAL are available in the company’s newsroom at https://ibn.fm/HWAL

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Friday, January 29th, 2021 Uncategorized Comments Off on $HWAL Is ‘One to Watch’

$UUUU Enters Strategic Partnership to Reestablish US REE Production

Energy Fuels (NYSE American: UUUU) (TSX: EFR), a leading U.S.-based uranium mining company, is positioned in what could be called a milestone moment in re-establishing a fully integrated rare earth element (“REE”) supply chain in the United States. The company recently announced a three-year supply agreement with the Chemours Company (NYSE: CC), under which it will receive a minimum of 2,500 tons of natural monazite ore per year, one of the highest-grade rare earth element (“REE”) minerals in the world. Energy Fuels will process this monazite at its 100%-owned White Mesa Mill in Southeast Utah to produce a marketable mixed REE carbonate. “We are extremely excited about working with Chemours to help reestablish U.S. rare earth production,” said Energy Fuels president and CEO Mark S. Chalmers in a recent update. “Chemours is a leader in the U.S. heavy mineral sands industry, and together we are now taking an important first step in returning the REE supply chain back to the United States. We look forward to working with Chemours in the future to expand our mutual contributions to this important initiative.”

To view the full article, visit https://ibn.fm/FhVTg

About Energy Fuels Inc.

Energy Fuels is a leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant, and anticipates commencing commercial production of rare earth element (“REE”) carbonate in 2021. Its corporate offices are in Lakewood, Colorado, near Denver, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year, has the ability to produce vanadium when market conditions warrant and is completing final test-work for the production of REE carbonate from various uranium-bearing ores. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U3O8 per year. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol “UUUU,” and the company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.” For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

About MiningNewsWire

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com

MiningNewsWire is part of the InvestorBrandNetwork.

Friday, January 29th, 2021 Uncategorized Comments Off on $UUUU Enters Strategic Partnership to Reestablish US REE Production

$CLXPF You Don’t Have to Take Psychedelics to Benefit from Them – Here’s How

Psychedelics have been in the spotlight for quite a while now and may be here to stay, given the immense therapeutic potential various psychedelic substances have demonstrated. For instance, psilocybin mushrooms have been used in therapeutic settings to help deal with various psychiatric disorders such as anxiety or addiction; the state of Oregon as gone so far as to legalize its medicinal use.

In addition to this, MDMA phase 3 trials are currently being conducted, with many predicting that there could be an FDA-approved MDMA prescription treatment by the year 2023. Researchers are studying MDMA and its efficacy in the treatment of post-traumatic stress disorder.

It should be noted, however, that individuals who have epilepsy, bipolar type II or I, schizophrenia, psychosis or paranoid should not indulge in any psychedelic substances or partake in their consumption. This also applies to individuals with liver disease, hypertension and heart issues as well as people who have issues with substance abuse.

The revolution of psychedelics has begun, with many feeling hopeful regarding the future of psychedelic science. While no one is encouraged to participate or indulge in psychedelics recreationally, acquiring knowledge about how they may improve mental health without you having to consume them will do you no harm. Here’s how you can still benefit from these substances without consuming them directly.

Psychedelic-assisted therapy may improve overall societal mental health

While the West does not view mental health as a public issue, particular medicinal traditions in other parts of the world have a practice that allows a medicine healer to take a medicine on behalf of another individual. This indirect healing has been observed in various Native American communities and in some African traditions. The shamans of the Shipibo tribe of Amazon have been known to drink ayahuasca, a hallucinogen, on behalf of burdened members of their communities.

Various estimates show that MDMA-assisted therapy will save hundreds of millions of dollarsfor decades to come for institutions such as the U.S. Veterans Affairs Department. Mental health issues such as depression, addiction and PTSD have been known to cause unemployment and increase suicide rates. Therefore, bettering the society’s mental health may in turn improve other aspects of society and benefiting members of society as well.

Psychedelics have developed the science of mental health

Before the 1950s, SSRI antidepressants did not exist. It was the discovery of LSD and its potential that prompted advancements in the field of neurochemistry that resulted in their development.

Currently, roughly 33% of individuals suffering from depression don’t respond to SSRIs. This is where ketamine comes in. Ketamine is a medication found to be effective in treating depression. The drug works by growing an individual’s synapses and strengthening their brain neurons. Close friends and family who may be living with depression may have their symptoms alleviated through ketamine therapy, which provides immense relief to caregivers, thus providing a benefit to both the individuals dealing with depression as well as their loved ones and caregivers.

Ketamine isn’t the only psychedelics-based therapy being studied for potential treatment use. In fact, Cybin Inc. (NEO: CYBN) (OTC: CLXPF) has a number of therapeutic products under development. One notable product is PY001, a psilocybin sublingual film undergoing clinical trials for its efficacy as an alternative to psilocybin pills.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTC: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Friday, January 29th, 2021 Uncategorized Comments Off on $CLXPF You Don’t Have to Take Psychedelics to Benefit from Them – Here’s How

$BHAT Announces Preliminary Q4 2020 Financial Results

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT), a leading producer, developer and operator of augmented reality (“AR”) interactive entertainment games, toys and educational materials in China, today announced preliminary unaudited financial results for the fourth quarter ended Dec. 31, 2020. According to the update, the company’s total revenues increased more than 70% to approximately US$20 million, compared to US$11.8 million in the prior-year period. “We are pleased with the top-line growth achieved during the 2020 fourth quarter. This was primarily driven by revenues from our strategic acquisition of Xunpusen, which has set a strong foundation for us to be able to execute an effective sales and marketing strategy for our AR, education, and mobile game products by leveraging their expertise in enterprise software solutions and mobile sales to promote products directly to customers,” Blue Hat CEO Xiaodong Chen said in the news release. “Xunpusen’s partnership with China Mobile, announced in November of last year, will serve to increase these sales channels and strengthen Blue Hat’s brand as a recognized leader in interactive entertainment and education technologies and implementation.”

To view the full press release, visit http://ibn.fm/4IVUi

About Blue Hat

Blue Hat Interactive Entertainment Technology is a producer, developer and operator of AR interactive entertainment games and toys in China, including interactive educational materials, mobile games and toys with mobile-game features. The company’s entertainment platform creates unique user experiences by connecting physical items to mobile devices, which creates a rich visual and interactive environment for users through the integration of real objects and virtual scenery. Distinguished by its own proprietary technology, Blue Hat aims to create an engaging, interactive and immersive community for its users. For more information, please visit the company’s investor relations website at www.IR.BlueHatGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to BHAT are available in the company’s newsroom at http://ibn.fm/BHAT

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Friday, January 29th, 2021 Uncategorized Comments Off on $BHAT Announces Preliminary Q4 2020 Financial Results

$MGROF Announces Promising Results from CyberAgrot Study

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an innovative agriculture biotech company focused on providing natural biological protection for high value crops, recently released potentially industry-changing results for its initial Colombia laboratory test. The study evaluated the effect of its proprietary mustard-derived organic biopesticide formulation on the disease Fusarium wilt TR4. MustGrow’s study, conducted and reported via third-party laboratory CyberAgrot SAS in Colombia using Instituto Colombiano Agropecuario (“ICA”) official protocols, reported 100% control of the disease. A recent article discussing this reads, “In the announcement, MustGrow outlined the CyberAgrot study results. Carefully adhering to ICA official protocols, the test evaluated samples treated with MustGrow’s natural organic biopesticide as well as control samples that were left untreated. The study tested five different rates, and all data was measured after a five-day period. In all samples, MustGrow’s biopesticide showed 100% control of Fusarium wilt TR4. By contrast, all of the control samples showed Fusarium wilt TR4 still growing.”

To view the full article, visit: https://ibn.fm/VcoAo

About MustGrow Biologics Corp.

MustGrow is a publicly traded agriculture biotech company focused on providing natural science-based biological solutions for high value crops, including fruits and vegetables. MustGrow has designed and owns a United States EPA-approved natural solution that uses the mustard seed’s natural defense mechanism to protect plants from pests and diseases. Over 110 independent tests have been completed, validating MustGrow’s safe and effective signature products. The product, in granule format, is EPA-approved across all key U.S. states and by Health Canada’s PMRA (Pest Management Regulatory Agency) as a bio-pesticide for high value crops such as in fruit and vegetables. MustGrow has now concentrated a liquid format, TerraMG, which, with regulatory approval, could be applied through standard drip or spray equipment, improving functionality and performance features. For more information, visit the company’s website at www.MustGrow.ca.

NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at http://ibn.fm/MGROF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Friday, January 29th, 2021 Uncategorized Comments Off on $MGROF Announces Promising Results from CyberAgrot Study

$NETE $MSFT Acquires Stake in Self-Driving EV Venture

The electric vehicle (“EV”) sector is one of the hottest industries right now — and for good reason. Everyone wants a piece of the electric action, from EV start-ups and veteran automakers to companies that didn’t even dabble in the auto industry in the first place. Tesla may currently be at the top of the EV game, but it will have to contend with several players battling to secure a share of the young EV industry as time passes.

Microsoft Corp. (NASDAQ: MSFT), a company primarily known for developing, manufacturing, licensing and selling computer software, electronics and personal computers, has announced that it has strategically teamed up with General Motors Co. (NYSE: GM) together with Cruise LLC to help develop and commercialize self-driving cars. Based in San Francisco, California, Cruise LLC has GM as a majority stakeholder with a goal to develop the world’s most advanced self-driving, fully electric, shared vehicles.

The California-based self-driving car has received more than $2 million in equity investment from GM, Microsoft and Honda Motors (OTC: HNDAF) as well as other institutional investors, bringing its valuation to $30 billion. According to Cruise, Microsoft will help accelerate the commercialization of its all-electric, shared, self-driving vehicles. The three companies will collaborate on cloud computing, software and hardware engineering, partner ecosystem and manufacturing.

More specifically, Cruise will use Microsoft’s cloud computing service Azure to commercialize its self-driving electric vehicles on a larger scale. The 10-year-old cloud and edge computing platform was designed to build, test, deploy and manage applications through data centers managed by Microsoft. This technology will allow Cruise to “unlock the potential of cloud computing” for autonomous vehicles, Microsoft says. Microsoft will in turn leverage the industry insight it gained from working with Cruise to develop technology for automotive companies and expand into the transportation industry.

GM chairman and CEO Mary Barra has called Microsoft a great addition to the team as it continues to look toward achieving zero emissions and zero congestion. On top of accelerating Cruise’s efforts to start earning a profit from its autonomous vehicles, Microsoft will also lend its cloud computing expertise to GM, which plans to launch 30 new electric vehicle models globally by 2025.

General Motors will leverage Microsoft’s expertise to help speed digitization initiatives such as artificial intelligence, machine learning, collaboration and storage. Microsoft’s cloud computing expertise will also help General Motors scout for opportunities to streamline its operations across digital supply chains, increase employee productivity and increase the speed at which customers get new mobility services.

Meanwhile, Net Element (NETE), a leading global fintech company, is in the process of completing a reverse merger with Mullen Technologies Inc., a manufacturer of electric vehicles. The resulting company will be one to watch.

NOTE TO INVESTORS: The latest news and updates relating to Net Element (NASDAQ: NETE) are available in the company’s newsroom at http://ibn.fm/NETE

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

Friday, January 29th, 2021 Uncategorized Comments Off on $NETE $MSFT Acquires Stake in Self-Driving EV Venture

$SRAX BIGToken Announces Closing of Share Exchange Agreement with Force Protection Video Equipment Corp. (FPVD)

BIGToken, Inc. this morning announced the closing of its share exchange transaction with Force Protection Video Equipment (OTC: FPVD) resulting in BIGToken now being a public company by way of a reverse merger. FPVD issued SRAX (NASDAQ: SRAX), the parent company of BIGToken, a total of 149,562,566,584 shares of common stock in exchange for 100% of the issued and outstanding shares of BIGToken, per the terms of the share exchange agreement dated September 30, 2020, as amended. Additionally, FPVD issued 7,000,000,000 shares of common stock and 8,318 shares of its C convertible stock, convertible into a total of 9,991,922,638 shares of common stock, subject to certain ownership limitations, which were issued in exchange for promissory notes totaling $815,520 plus accrued interest of $32,597.

To view the full press release, visit http://ibn.fm/EnTJ2

About SRAX

SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, please visit www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Wednesday, January 27th, 2021 Uncategorized Comments Off on $SRAX BIGToken Announces Closing of Share Exchange Agreement with Force Protection Video Equipment Corp. (FPVD)

$SRAX Censorship and Data: The Stakes and Consequences Are Getting Serious

NetworkNewsWire Editorial Coverage: A recent Pew Research article pinpointed major concerns with social media platforms. “Americans have complicated feelings about their relationship with big technology companies,” the article observes. “While they have appreciated the impact of technology over recent decades and rely on these companies’ products to communicate, shop and get news, many have also grown critical of the industry.” The article goes on to report that a Pew Research Center survey found that “roughly three-quarters of U.S. adults say it is very (37%) or somewhat (36%) likely that social media sites intentionally censor political viewpoints that they find objectionable. Just 25% believe this is not likely the case.” The events of the last few weeks have made that article appear almost prophetic as issues of censorship and privacy have gained additional prominence on the world stage. A number of private and public companies are working to resolve these issues, with many of those companies relying on blockchain to provide their services. Leading the pack is BIGtoken, the first consumer-managed data marketplace where people can own and earn from their data. The opportunity ahead has such potential that parent company SRAX Inc. (NASDAQ: SRAX) is spinning out BIGtoken into a separate publicly traded company and has entered into a definitive share exchange agreement with Force Protection Video Equipment Corp. (OTC: FPVD). The separation of BIGtoken provides shareholders a pure play in the consumer-managed data sector. SRAX benefits from the potential upside of the BIGtoken platform while reducing operating costs. Social media behemoths such as Facebook Inc. (NASDAQ: FB) and Twitter Inc. (NYSE: TWTR) are under pressure to identify and remove hate-filled communication along with taking added measures to protect consumer data. Blockchain companies such as Riot Blockchain Inc. (NASDAQ: RIOT) could benefit from increased implementation of blockchain technology to protect consumers, safeguard information and ensure data privacy. Everyone’s at risk as revealed by the recent Solarwinds hack, which compromised not just local, state and federal agencies but also major tech companies as well.

  • Consumers starting to more deeply question growing censorship issues, lack of data control.
  • Using blockchain, BIGtoken is first consumer-managed data marketplace where users can own, earn from their data.
  • BIGtoken CEO writes that Privacy is fundamental human right whose time has come, and BIGtoken is pioneering the way forward.

Growing Concerns Surrounding Censorship, Privacy

Large social media sites now wield enormous power as they have become the dominant platforms of opinion and information. As they grew, they have used their codes of conduct to restrict certain opinions which is causing consumers to be acutely aware of the value of their personal data and driving them to alternative networks.

The issue of censorship on social media sites has never been more compelling — or divisive. A Jan. 14, 2021, Harvard Business Review article reported that “after years of controversy over President Trump’s use of social media to share misleading content and inflame his millions of followers, social media giants Facebook and Twitter finally took a clear stand last week, banning Trump from their platforms — Facebook indefinitely, and Twitter permanently.

“Could this indicate a turning point in how social media companies handle potentially harmful content shared on their platforms? And could it herald a new era of social media reforms, through both government policies and self-regulation? For many, Facebook and Twitter’s bans were long-awaited. But it’s not so cut and dry, as many others have decried these decisions as infringements on free speech.”

An “Observer Research Foundation” article stated that social media “is facing increasing pressure from both politicians and activists throughout the world as fake news and propaganda have found a fertile ground on these new platforms.” The article notes that “tech giants are trapped in a tricky dilemma — how to save freedoms on the Internet and limitedly restrict them at the same time, and how not to overreact. . . . Tagging controversial posts with warnings and blocking radical points of views — seem to be reasonable in today’s world.”

Censorship is a matter of perspective depending which side you’re on, but it isn’t the only issue rising to the fore. A recent Forbes article noted that “data privacy has become one of the defining social and cultural issues of our era.” The article, which noted that “people are starting to more deeply question their growing lack of data privacy and control,” shines a glaring spotlight on today’s growing challenge of data privacy. The article reports that “roughly six-in-ten U.S. adults say they do not think it is possible to go through daily life without having data collected about them by companies or the government.”

Providing Consumers with Choice

In the face of mounting concern about censorship and privacy, BIGtoken has tackled these problems early and head on. Through a transparent platform and consumer-reward system, BIG provides consumers with choice, transparency and compensation for their data. The system also provides advertisers and media companies access to transparent, verified consumer data to better reach and serve audiences.

Available for download on the App Store and Google Play, the BIGtoken app enables its rapidly growing 16-million-plus members to choose what data they want to share, as well as which companies can buy that data and how that data is used. Users provide data by answering questions, taking surveys and connecting various online accounts. BIGtoken then anonymizes the data, sells it to brand advertisers and shares the revenue with its users.

What’s more, when BIGtoken users choose to share their data anonymously, they receive rewards in the form of cash or gift cards; they can even deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart. And users with philanthropic desires can donate their rewards to several high-profile, nonprofit associations.

BIGtoken users aren’t the only beneficiaries. Advertisers and marketers that purchase access to anonymized segments of information from BIGtoken know that the data they receive is consumer verified and in compliance with the growing number of consumer privacy acts enacted not only in the United States but around the world. BIG’s exclusive technology provides vetted data for brands in the CPG, investor relations, luxury and lifestyle verticals.

A New Era

Gig data and business analytics solutions is a booming business, one that is projected to reach $260 billion globally by next year. Those numbers make the space extremely attractive to companies with the technology, background and expertise to succeed. Launched in 2018, BIGtoken appears to be one of those companies.

Most recently, the company has added to its executive leadership strength with the appointment of crypto pioneer and digital media veteran Lou Kerner as CEO. Upon completion of the definitive agreement with Force Protection Video Equipment Corp, FPVD will be renamed BIGtoken Inc. with Kerner as CEO.

“I’ve been deeply interested in privacy since 2003 when I was running Bolt,” said Kerner. “And my interest in crypto has also been fueled, in part, by its privacy features. As the world continues to move to ensure greater internet privacy for consumers, BIGtoken is well-positioned to help brands, media companies, research organizations and political campaigns efficiently reach consumers via compliant ad targeting and surveys. I further believe BIGtoken will greatly benefit by fully embracing crypto as an alternative reward for our growing consumer base.”

The cause of data privacy is supported by BIGtoken. “Privacy is a fundamental human right whose time has come, and BIGtoken is helping lead the way, says Kerner in an article titled “The 5 Reasons I’m Joining BIGtoken as CEO.” Kerner points out that data privacy isn’t new, but the attitude shift by individuals, corporations and regulators/government is. “A new era of data privacy is, finally, upon us,” states Kerner, whose expertise in cryptocurrency and blockchain brings an added level of expertise and insight to the company.

A Delicate Balance

Companies on the front lines are trying to balance free speech and public safety while addressing issues of censorship and data privacy as solutions may be found in blockchain utilization.

Facebook Inc. (NASDAQ: FB) has developed a set of community standards that outline what is and is not allowed on Facebook. “We recognize how important it is for Facebook to be a place where people feel empowered to communicate, and we take seriously our role in keeping abuse off our service,” the company states. “Our policies are based on feedback from our community and the advice of experts in fields such as technology, public safety and human rights. To ensure that everyone’s voice is valued, we take great care to craft policies that are inclusive of different views and beliefs, in particular those of people and communities that might otherwise be overlooked or marginalized.”

Twitter Inc.’s (NYSE: TWTR) purpose is “to serve the public conversation.” The company’s guidelines note that “violence, harassment and other similar types of behavior discourage people from expressing themselves, and ultimately diminish the value of global public conversation. Our rules are to ensure all people can participate in the public conversation freely and safely.” In addition, Twitter believes that a user should “always know what data we collect from you and how we use it, and that you should have meaningful control over both.”

One of the largest U.S.-based, publicly traded Bitcoin miners in North America, Riot Blockchain Inc. (NASDAQ: RIOT) is focused on gaining exposure to the blockchain ecosystem through its cryptocurrency mining operations, internally developed businesses and joint ventures. The company’s primary focus is on Bitcoin and general blockchain technology, the same blockchain technology being used by many companies to ensure data privacy and protection.

For more information about Force Protection Video Equipment Corp (OTC: FPVD), please visit Force Protection Video Equipment Corp.

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 40+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

Wednesday, January 27th, 2021 Uncategorized Comments Off on $SRAX Censorship and Data: The Stakes and Consequences Are Getting Serious

$POAI Closes Registered Direct Offering for $4.1 Million

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed of its previously announced registered direct offering. The offering comprised 3,414,970 shares of POAI’s common stock, offered at a purchase price of $1.20 per share, which was priced at-the-market under Nasdaq rules. The announcement noted that gross proceeds from this offering for Predictive Oncology will total approximately $4.1 million, before fees and other offering expenses are deducted. POAI anticipates using net proceeds from the offering for working capital projects and purposes.  The company also announced a concurrent private placement. That placement was issued to the same investors and was comprised of unregistered warrants to purchase up to 1,707,485 shares of common stock at an exercise price of $1.37 per share. The warrants have a five-and-one-half-year term. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

To view the full press release, visit: https://ibn.fm/I5CFV

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (domestic, international and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Soluble Biotech.  Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA (“DNA/RNA”) and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. For more information about the company, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Wednesday, January 27th, 2021 Uncategorized Comments Off on $POAI Closes Registered Direct Offering for $4.1 Million

$GNPX CEO to Present at Upcoming Virtual Investor Conference Small and Microcap Showcase

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, this morning announced that the company’s president and CEO Rodney Varner will present at the Virtual Investor Conference Small and Microcap Showcase at 11 AM ET on February 4, 2021. Varner will be providing a virtual company overview, including a synopsis of its diabetes gene therapy and details on the recent progress made on GNPX’s upcoming clinical trials for the treatment of non-small cell lung cancer. Following the conference, a replay of GNPX’s presentation will be available on the company’s website for a limited time. A video will also be archived on www.VirtualInvestorConferences.com.

To register for the event, visit https://ibn.fm/VSD9k

To view the full press release, visit https://ibn.fm/9Lkao

About Genprex Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, REQORSA(TM) (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Wednesday, January 27th, 2021 Uncategorized Comments Off on $GNPX CEO to Present at Upcoming Virtual Investor Conference Small and Microcap Showcase

$DRIO Signs Agreements to Acquire Leading Digital Musculoskeletal Company, Raise $70 Million Through Private Placement

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced that it has entered into a definitive agreement to acquire Upright Technologies Ltd., a digital musculoskeletal (“MSK”) company; the acquisition will be in the form of a stock transaction. The acquisition is designed to expand DarioHealth’s multi-condition platform into the $213 billion musculoskeletal market and create one of the most comprehensive digital health platforms. The move also brings together complementary companies with industry-leading consumer engagement and clinical outcomes. In addition, DRIO has entered into definitive agreements with a group of health-care institutional investors to raise $70 million through a private placement. That financing includes several leading health-care focused institutional investors such as Nantahala Capital Management LLC, Perceptive Advisors, Driehaus Capital Management, Farallon Capital Management, Pura Vida Investments, and others. “I am very pleased to be able to achieve this milestone and expect that MSK will be a meaningful growth driver for our company for years to come,” said Dario CEO Erez Raphael in the press release. “We are committed to delivering the industry’s most comprehensive, clinically proven solution for the management of chronic conditions, and the addition of Upright, which is an expansion of our core competency, represents a significant step toward that goal. With similar approaches to building highly engaging and clinically effective products and similar cultures, I anticipate a rapid and seamless integration.”

To view the full press release, visit: https://ibn.fm/VtZff

About DarioHealth Corp.

DarioHealth is a leading global, digital-therapeutics company revolutionizing how people with chronic conditions manage their health. By delivering evidence-based interventions driven by connected devices, data, high-quality software and coaching, the company makes the right thing to do the easy thing to do. The company’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology. Dario offers one of the highest-rated diabetes and hypertension solutions on the market; its highly engaging, user-centric MyDario(TM) mobile app is used regularly by tens of thousands of consumers worldwide. The company is rapidly expanding into new chronic conditions and geographic markets, using a performance-based approach to improve its users’ health. For more information about the company, please visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Wednesday, January 27th, 2021 Uncategorized Comments Off on $DRIO Signs Agreements to Acquire Leading Digital Musculoskeletal Company, Raise $70 Million Through Private Placement

$DRIO New Study Discovers Patient’s Immune System Continues Building Resistance After Recovering from COVID-19

The novel coronavirus has affected many countries, infecting roughly 96.2 million people across the globe. Of the 96 million individuals, about 53 million have recovered from this disease while nearly 2 million individuals have, sadly, succumbed to the deadly infection.

Researchers have been trying to figure out how long the immunity of an individual who recovered from the disease will last. A recent study by Rockefeller University researchers provides an answer to this, suggesting that individuals who recover from the coronavirus are protected against the deadly infection for about six months, and likely much longer.

The study’s findings provide strong evidence showing that the immune system remembers the infection and continues to provide better antibodies even after the infection has subsided. The researchers discovered that the antibodies that are produced months after the infection had waned demonstrated an added ability to obstruct SARS-CoV-2 as well as the mutated versions of this infection. The researchers also discovered that continued exposure of immune cells to the virus remnants that were found in the gut tissue led to the production of improved antibodies.

Based on these discoveries, researchers surmise that when individuals who have recovered from the infection encounters the virus again, their immune response would not only be more effective but would also be more rapid, thus preventing re-infection.

Prof. Michel C. Nussenzweig, the head of Rockefeller’s laboratory of molecular immunology, whose team has been studying the response of antibodies in coronavirus patients, explained that the type of immune response that had been observed during the study could potentially be used to offer protection from the virus for a while, which would allow an individual’s body to prepare an effective and fast response to the virus upon re-exposure.

In order to understand how the antibodies worked in SARS-CoV-2, Nussenzweig and his team observed the responses of antibodies in 87 participants: the first time one month after the participants had been infected with the virus and a second time six months later.

They discovered that while the antibodies could still be detected at the second timepoint, their numbers had decreased significantly. Laboratory experiments conducted demonstrated that the ability of the plasma samples extracted from a patient to wipe out the virus had declined by about five times.

The researchers also looked into the SARS-CoV-2 virus replicating some of its cells in small intestine, upper throat and lung tissue. To help with this, the team collaborated with former Rockefeller scientist Saurabh Mehandru, who has been studying intestinal tissue biopsies from individuals who had recovered from the coronavirus.

They found that of the 14 patients who had tests conducted on them, seven of them had the genetic material and proteins of SARS-CoV-2 in the cells that line their intestines. The team of researchers is planning on studying more patients in a bid to better understand the role these viral remnants play both in an individual’s immunity and the disease’s progression.

Away from Sars-Cov-2, chronic noncommunicable diseases such as diabetes have been taking a toll on communities, and many companies are taking steps to address the treatment needs of the affected people. An example is DarioHealth Corp. (NASDAQ: DRIO), a company that has at least 51,000 active users of their smartphone-based digital solution that makes it easier for patients to make lasting lifestyle changes in order to lower the toll of their health conditions.

NOTE TO INVESTORS: The latest news and updates relating to DarioHealth Corp. (NASDAQ: DRIO) are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Wednesday, January 27th, 2021 Uncategorized Comments Off on $DRIO New Study Discovers Patient’s Immune System Continues Building Resistance After Recovering from COVID-19

$CLXPF Advocates Worried by Insufficiency of Information on Psychedelic Treatments in Nova Scotia

Justin Andrews, co-founder of Halifax Psychedelic Society, a not-for-profit organization providing a safe space to connect and talk about psychedelics, is concerned that information on harm minimization strategies with regard to psychedelics is not being treated as a priority in Nova Scotia.

Andrews assisted in the establishment of the organization in 2018. The objective of the organization was to offer harm-reduction information and a support system to individuals who would be interested in using psychedelic substances such as LSD and psilocybin as a therapeutic treatment.

In this respect, harm-minimization strategies would comprise information about how to consume the psychedelic substances properly. This may also include how to prepare the said drug as well as dosage levels. In addition, it could also include insights on how to manage a “bad trip”, or a disagreeable experience that is usually set off by hallucinogenic drugs.

Andrews explained that while it wasn’t until 2016 that he began taking interest in psychotherapy using psychedelics, harm minimization had always been a priority.

Both the society and Andrews are supportive of the legal use of psychedelic substances in psychotherapy. Andrews explained that he had observed a surge in interest from individuals who sought out information about the use of psychedelics. This, he said, was the reason why it was important to have harm-reduction resources available to individuals in Nova Scotia.

Additionally, Andrews observed that there was an increasing trend in underground therapy. With people excited about the healing potential of psychedelics, it was important to emphasize the need for individuals to know and understand the policy and politics behind psychedelics.

At the moment, the Nova Scotia Health Authority does not provide any harm-minimization information on psychedelics except when it’s included in a treatment plan for addiction.

Society president Jeff Toth, who is also a psychiatric nurse, explained that recent studies have discovered the therapeutic benefits of various psychedelics such as MDMALSD and psilocybin and how they can be used to treat addiction, depression and even post-traumatic stress disorder. However, he added that more research was required as the evidence that had been gathered till now was regarded as preliminary evidence.

A study that was conducted by the “British Journal of Psychiatry” categorized Canada as the country with the highest PTSD prevalence of the 24 nations involved in the study.

However, it seems a lot more will be required for NSHA to start providing harm-minimization literature. NSHA’s mental health and addictions department stated in an email that the Nova Scotia Health Authority had no plans to release harm-minimization literature on the therapeutic use of psychedelics as it had not encountered a high demand for that information thus far.

As research into psychedelics advances, many companies are positioning themselves to tap the growing market. For instance, Cybin Inc. (NEO: CYBN) (OTC: CLXPF) is developing unique systems to deliver psychedelic medicines for a variety of therapeutic indications.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTC: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Wednesday, January 27th, 2021 Uncategorized Comments Off on $CLXPF Advocates Worried by Insufficiency of Information on Psychedelic Treatments in Nova Scotia

$CNSP Discusses Product Pipeline, Clinical Trial Plans, at H.C. Wainwright Bioconnect 2021 Virtual Conference

  • Company will initiate a Phase II adult trial for Berubicin this year focused on patients with glioblastoma multiforme
  • WPD, a CNS sub-license partner, will be commencing a parallel Phase II adult trial and the first-ever pediatric Berubicin trial
  • Additional clinical trials are in the pipeline, including one for the company’s newest drug candidate, WP1244, and its effects on central nervous system tumors

Biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP) recently took part in the H.C. Wainwright Bioconnect 2021 Virtual Conference, which took place January 11-14, 2021. CNS’s CEO John Climaco gave a presentation at the event, discussing how the clinical-stage biopharmaceutical company is developing novel treatments for primary and metastatic cancers of the brain and central nervous system (https://ibn.fm/7zYST).

CNS’s lead drug candidate is Berubicin, an anthracycline that, based on clinical data, can cross the blood-brain barrier in adults and reach the tumor cells of patients with brain cancer. As an organ targeted therapeutic, Berubicin demonstrated one durable complete response (not detectible on imaging) in a Phase I trial completed by Reata Pharmaceuticals, Inc. (NASDAQ: RETA) 14 years ago. CNS currently holds the worldwide exclusive licensing to the Berubicin drug and it recently obtained Investigational New Drug designation for it from the Food and Drug Administration.

In addition to Berubicin, the company’s current developmental pipeline includes a second promising drug candidate, WP1244. Licensed from The University of Texas MD Anderson Cancer Center in the first quarter of 2020, WP1244 is a DNA-binding agent that represents a novel class of potential therapeutics.

WP1244 is designed using anthracycline and distamycin-based scaffolds, creating small molecule agents binding extended sequences of DNA. In vivo testing demonstrated high uptake with WP1244 in the brain and subsequent antitumor activity in orthotopic models of the brain. The drug candidate is believed to be 500 times more potent than daunorubicin in inhibiting tumor cell proliferation. CNS entered into a Sponsored Research Agreement with MD Anderson Cancer Center in May 2020, related to WP1244.

CNS Pharmaceuticals, in partnership with company sublicensee WPD Pharmaceuticals, Inc. (CSE: WBIO) (FSE: 8SV1) currently has several clinical trials in different stages of preparation, including three glioblastoma multiforme (“GBM”) studies for Berubicin, scheduled to begin in Q1 2021. These include a randomized, controlled Phase II trial in the United States and another Phase II in Poland, conducted by WPD. Both these studies will be conducted with adult candidates. WPD will also begin the first-ever Phase I pediatric trial with Berubicin in Poland. Other studies in the pipeline for a future date include a potential Phase I trial for Berubicin with pancreatic and ovarian cancer and lymphoma patients as well as a potential Phase I trial for WP1244 for central nervous system tumors.

The primary focus for Berubicin has been patients with GBM, one of the most aggressive forms of brain cancer currently considered incurable. Each year, nearly 15,000 new GBM patients are being diagnosed in the United States. With the optimal therapy (surgical resection, chemotherapy, radiation), the median survival rate is only 15-23 months. Nearly 100% of GBM tumors recur after first-line therapy.

The Phase II trials for Berubicin in adult candidates are designed to be:

  • Adaptive – the trial is designed to allow for modifications based on accumulated data from trial subjects
  • Randomized – the trial randomizes which patients receive Berubicin versus the control group, eliminating the bias and increasing statistical significance
  • Controlled – a control arm receiving the standard of care to compare the effectiveness of Berubicin against this standard, increasing the statistical significance
  • Potentially Pivotal – the trials are designed to provide, pending positive results, the data necessary to support CNS’s request to the FDA for an expedited pathway to further development or approval of Berubicin

CNS believes that Berubicin has the potential to become a standard of care for GBM and other forms of brain cancer. The current first-line therapy includes temozolomide (“TMZ”). Nearly 40% of patients are genetically predisposed to respond to, becoming resistant to the treatment quickly. Berubicin could potentially be a second-line drug in these cases. The remaining 60% of patients may not be affected by TMZ, making Berubicin a potential first choice.

At the close of the presentation, Climaco said the company expects to see the first data for the Phase II trial in Poland reported during the third or fourth quarter of this year.

For more information, visit the company’s website at www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Wednesday, January 27th, 2021 Uncategorized Comments Off on $CNSP Discusses Product Pipeline, Clinical Trial Plans, at H.C. Wainwright Bioconnect 2021 Virtual Conference

$CNPOF to Release Q3 Financial Results, Host Conference Call on February 10

Canopy Rivers (TSX: RIV) (OTC: CNPOF) today announced that it will be releasing its third quarter fiscal year 2021 financial results before markets open on February 10, 2021. Detailed information regarding the company’s financial statements for the three and nine months ended December 31, 2020 will be available on the company’s profile on www.SEDAR.com and on the company’s website at www.CanopyRivers.com/investors. The company will host a conference call and audio webcast following the release of its financial results at 9 AM ET on February 10. Canopy Rivers President and CEO Narbe Alexandrian, Chief Strategy Officer and General Counsel Matt Mundy and CFO Eddie Lucarelli will host the call. A live audio webcast will be available online (https://cnw.fm/c3UOH). To join the call, dial the North American toll-free number at 1-888-390-0546 and use the confirmation # 18291365. A replay of the call will be available through February 17 by dialing 1-888-390-0541 and entering the replay code 291365 #.

To view the full press release, visit: https://cnw.fm/iJTCD

About Canopy Rivers Inc.

Canopy Rivers is a venture capital firm specializing in cannabis with a portfolio of 17 companies across various segments of the cannabis value chain. The company believes that bringing together people, capital and ideas raises the potential of the entire cannabis industry. By leveraging industry insights, in-house expertise and thesis-driven approach to investing, Canopy Rivers aims to provide shareholders exposure to specialized and disruptive cannabis companies. Canopy Rivers’ mission is to invest in innovators across the cannabis value chain, help them grow, and ultimately create value by guiding these companies towards a monetization event. Together with its portfolio, the company is helping build the cannabis industry of tomorrow, today. For more information, visit www.CanopyRivers.com.

NOTE TO INVESTORS: The latest news and updates relating to CNPOF are available in the company’s newsroom at http://cnw.fm/CNPOF

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Wednesday, January 27th, 2021 Uncategorized Comments Off on $CNPOF to Release Q3 Financial Results, Host Conference Call on February 10

$BHAT Regains Compliance with Nasdaq Minimum Bid Price Requirement

XIAMEN, China Jan. 27, 2021 Blue Hat Interactive Entertainment Technology (“Blue Hat” or the “Company”) (NASDAQ: BHAT) , a leading producer, developer and operator of augmented reality (“AR”) interactive entertainment games, toys and educational materials in China , today announced it received a letter from the Nasdaq Stock Market LLC notifying the Company that it has regained compliance with the Nasdaq Capital Market’s minimum bid price requirement. The letter noted that as of January 25, 2021, Blue Hat evidenced a closing bid price of its ordinary shares in excess of the $1.00 minimum requirement for the past 10 consecutive business days. Accordingly, Blue Hat has regained compliance with Nasdaq Marketplace Rule 5550(a)(2), and Nasdaq considers the matter closed.

About Blue Hat

Blue Hat Interactive Entertainment Technology is a producer, developer and operator of AR interactive entertainment games and toys in China , including interactive educational materials, mobile games, and toys with mobile game features. The Company’s interactive entertainment platform creates unique user experiences by connecting physical items to mobile devices, which creates a rich visual and interactive environment for users through the integration of real objects and virtual scenery. Distinguished by its own proprietary technology, Blue Hat aims to create an engaging, interactive and immersive community for its users. For more information, please visit the Company’s investor relations website at http://ir.bluehatgroup.com . The Company routinely provides important information on its website.

Contacts :

Blue Hat Interactive Entertainment Technology
Phone: +86 (592) 228-0010
Email: ir@bluehatgroup.net

Investor Relations:
The Equity Group Inc.                                        In China
Adam Prior , Senior Vice President                     Lucy Ma, Associate
(212) 836-9606                                                   +86 10 5661 7012
aprior@equityny.com lma@equityny.com

Wednesday, January 27th, 2021 Uncategorized Comments Off on $BHAT Regains Compliance with Nasdaq Minimum Bid Price Requirement

$NETE A Peek into the Technology Keeping EV Cabins Quiet

After experiencing years of noisy cabins courtesy of internal combustion engine vehicles, most drivers who go green are often surprised by how quiet the cabins of electric vehicles (“EVs”) are. EVs have eliminated not just carbon emissions but sound pollution as well. Conventional vehicles are powered by a combustion engine, which can be quite loud, but electric vehicles rely on a much quieter electric motor for propulsion.

Unfortunately, without a loud combustion engine drowning everything out, ambient road noise is much more obvious inside the cabin. To eliminated this noise, EV makers have been using technology similar to what makes noise-canceling headphones so effective. Israel-based tech innovation company Silentium has created a special acoustic technology dubbed the Active Road Noise Cancellation (“ARNC”) software that can successfully keep ambient road noise out of the cabin.

After being selected by South Korean-based global automotive supplier Hyundai Mobis as its preferred noise-canceling technology supplier, Silentium is looking to roll out its personal in-car sound environments globally. Although ARNC technology shares some similarities with the technology in noise-canceling headphones, it is more advanced to deal with the much larger volumes of air in car cabins.

So how does it work?

Six accelerometers are strategically placed on the vehicle’s chassis to continually monitor unwanted noise from the road. Once the accelerometers detect noise, they dispatch a signal to a control unit onboard the vehicle. Equipped with Silentium’s noise-canceling software, the on-board control unit then emits an equal anti-noise signal using the speaker system of the vehicle. The waves from the ambient noise and the ANRC’s anti-noise signal hit the ears of the vehicle’s occupants simultaneously and neutralize each other, hence the silent cabin.

Silentium’s ANRC technology is proven to work across quite a wide spectrum of frequencies, from 20Hz up to 1kHz. The company’s partnership has allowed it to work with several automotive suppliers as well as some global original equipment manufacturers (“OEMs”). At the moment, three production models on the market are equipped with the noise-canceling technology.

Jaguar Land Rover was the first automaker to announce that it had integrated Silentium’s ARNC software in three of its upcoming models back in October 2020. This came after several years of development. The noise-canceling technology has been integrated into the Jaguar F-PACE, Jaguar XF and Range Rover Velar. Silentium and Hyundai are now working on a global vehicle production program for a still-unnamed brand.

Speaking of superior technologies, Net Element (NASDAQ: NETE) launched a blockchain-based system intended to avail safe platforms for payment processing. The company is also in the process of completing a merger with a California-based electric vehicle maker called Mullen Technologies Inc.

NOTE TO INVESTORS: The latest news and updates relating to Net Element (NASDAQ: NETE) are available in the company’s newsroom at http://ibn.fm/NETE

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

Monday, January 25th, 2021 Uncategorized Comments Off on $NETE A Peek into the Technology Keeping EV Cabins Quiet

$CLXPF Could Psychedelic Medicines Soon Be Widely Available in the UK?

Before psychedelic drugs returned to mainstream media, heralded and backed by all this new research that shows the therapeutic benefits and potential they may possess, many had known these substances to be drugs used by hippies and party-goers.

As the public perception of these substances changes, many ask, what is the possibility of the use of psychedelic medical treatment in the United Kingdom?

Last year, the MHRA (Medicines and Healthcare products Regulatory Agency) authorized a clinical trial that would look into the potential of DMT as a treatment for various mental health conditions, such as depression. In addition to this, the UK also plans to launch its first medical psychedelic health center in Bristol this year.

The clinic’s objective will be to provide psychedelic drug treatments for a range of disorders including addiction, depression, anxiety and post-traumatic stress disorder. Because ketamine is used as an anesthetic and a legal medical product in the UK, ketamine-assisted psychedelic psychotherapy will also be available at the clinic, with a limit of 30 to 40 patients every month.

Conversely, psilocybin and MDMA are classified in the schedule 1 of the Misuse of Drugs Regulations, 2001. In other words, this means that these substances cannot be prescribed legally outside a clinical setting despite their use in clinical trials. Additionally, for one to supply, possess or produce these substances, a Home Office license is needed.

The Bristol clinic will also provide therapists with training in psychedelics, as well as conduct more research into MDMA and psilocybin, which is the psychedelic compound found in magic mushrooms. This research will be used to back the utilization of these psychedelic substances in psychotherapy in the future.

This is not the only facility that intends to conduct more research on these substances, as there are various clinical research projects being carried out across the globe that have the same end goal: to gather the evidence required to back a meaningful change in policy on the legality of psychedelics.

For instance, COMPASS Pathways, a mental health-care firm based in London, was recently granted Breakthrough Therapy designation by the FDA for its psilocybin therapy program that is aimed at treatment-resistant depression in 2018.

AWAKN Clinic’s chief medical officer, Dr. Ben Sessa, also conducted a study that showed significant promise in the use of MDMA as an alternative treatment for alcohol use disorder. His research was reported in a recent “Neuropharmacology” journal.

Despite psychedelics being illegal in many countries across the globe, a shift can be seen in the way that the public perceives these substances.

A good example of this would be the voters from the state of Oregon, who approved a measure on their November 2020 ballot that legalized the therapeutic use of psilocybin. Canada also made it legal for patients who are terminally ill to use psilocybin as a part of their psychotherapy treatment.

Many hope that this will rub off on UK health officials, who seem opposed to embracing the potential that psychedelics possess.

In nearby Canada, Cybin Inc. (NEO: CYBN) is taking full advantage of the resurgent interest in psychedelics and functional mushrooms. The company has so far raised more than $8.2 million during its initial funding round.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Monday, January 25th, 2021 Uncategorized Comments Off on $CLXPF Could Psychedelic Medicines Soon Be Widely Available in the UK?

$POAI Closes Registered Direct Offering for $2.2 Million, Announces $4.1 Million Registered Direct Offering

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed on its previously announced registered direct offering; the company also announced that it has completed definitive agreements with a number of institutional and accredited investors for a registered direct offering. According to the announcement, POAI’s previously announced offering closed with 2,200,000 shares of common stock being sold, at a price of $1.00 per share. The gross proceeds for POAI was $2.2 million, with the company planning to use the funds for working capital purposes. Placement agent fees and other expenses related to the closing will be deducted from those proceeds. The company also announced that, in a concurrent private placement, it had issued to the same investors unregistered warrants to purchase up to 1,100,000 more shares of common stock; the exercise price for those will also be $1.00 per share. The cost for all shares was priced at-the-market under Nasdaq Rules. The newly announced registered direct offering comprises the issuance and sale of approximately 3,414,970 shares of POAI common stock. The offering is at a purchase price of $1.20 per share, also priced at-the-market under Nasdaq rules; the offering should result in gross proceeds of approximately $4.1 million for Predictive Oncology. All shares are part of POAI’s previously announced registered direct offering, filed with the Securities and Exchange Commission (“SEC”) in October 2019 with an effective date of Dec. 19, 2019.

To view both full press releases, visit https://ibn.fm/sqnsk and https://ibn.fm/W4KOJ

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (domestic, international and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Soluble Biotech.  Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA (“DNA/RNA”) and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. For more information about the company, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Friday, January 22nd, 2021 Uncategorized Comments Off on $POAI Closes Registered Direct Offering for $2.2 Million, Announces $4.1 Million Registered Direct Offering

$CRTD Announces Vocal Challenges Designed to Enhance User Participation in Creator Communities

Creatd (NASDAQ: CRTD), a proprietary technology platform for creators of all types, has unveiled two new creator challenges for its Vocal platform subscribers. The two challenges — Mystery of Bitcoin Challenge for all subscribers and  both freemium and premium Vocal+ paid subscribers and Hometown Feature challenge for Vocal+ subscribers — include cash prizes for the winners. The Mystery of Bitcoin Challenge focuses on the origins of cryptocurrency and invites Vocal creators to submit a fictional story about the who, how and why of Bitcoin’s origin as well as the identity of its unknown inventor. The Hometown Feature Challenge provides an opportunity for Vocal+ members to show off their favorite hometown locales by submitting original film photos, digital images, phone pictures, Polaroids or videos that capture what makes their hometown special. Vocal hosts these Challenges to give back to its creator communities throughout the year. “Vocal is a creator-first platform and, while brand participation is a key component of a Challenge’s success, it is important that we additionally maintain a regular stream of Vocal-sponsored Challenges to advance the voice of creativity,” said Creatd Founder, president and head of product Justin Maury in the press release. “Part of how we do that is by offering an array of Challenges along multiple subscription tiers. Vocal+ Challenges represent a significantly higher reward for participation while other Challenges offer less cash incentive but are still a great introductory opportunity for our freemium tier members. I am proud to announce that, as of today, we have a record number of six active Challenges currently open for participation.”

To view the full press release, visit https://ibn.fm/JJ0sG

About Creatd Inc.

Creatd empowers creators, brands and entrepreneurs through technology and partnership. Its flagship technology, Vocal, is a best-in-class creator platform. For more information about the company, please visit www.Creatd.com.

NOTE TO INVESTORS: The latest news and updates relating to CRTD are available in the company’s newsroom at http://ibn.fm/CRTD

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Friday, January 22nd, 2021 Uncategorized Comments Off on $CRTD Announces Vocal Challenges Designed to Enhance User Participation in Creator Communities